Cedilla Therapeutics today announced the appointment of veteran biopharma executive Rosana Kapeller, M.D., Ph.D., as an independent member of the board of directors. Kapeller, the former chief scientific officer at Nimbus Therapeutics, brings a wealth of experience in drug discovery, platform validation and corporate leadership.
“Rosana’s experience launching a successful biotech startup, building a robust drug discovery pipeline and ensuring sound corporate governance will be invaluable to us as we advance our mission to broaden the reach of small molecule therapeutics by harnessing protein stability mechanisms,” said Alexandra Glucksmann, Cedilla’s president and chief executive officer. “She is widely recognized as an exceptional leader and we are greatly looking forward to working with her.”
Kapeller spent more than eight years at Nimbus Therapeutics, leading the company’s drive to apply advanced computational technologies to the design and development of novel therapeutics. As Nimbus’s founding CSO, she assembled a strong scientific team that validated the company’s platform and advanced multiple promising programs. Before joining Nimbus, Kapeller served as founding vice president of research at Aileron Therapeutics. She started her career as a scientist at Millennium Pharmaceuticals, where she advanced through positions of increasing responsibility to director. Kapeller is an adviser to Atlas Ventures and has served as a consultant to Third Rock Ventures. She holds a Ph.D. in molecular and cellular physiology from Tufts University and a M.D. from Universidade do Estado do Rio de Janeiro in Brazil.
“Cedilla is pioneering new ways to leverage the cell’s intrinsic protein stability mechanisms for drug development,” Kapeller said. “I’m thrilled to join the board at this exciting time.”
About Cedilla Therapeutics
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.cedillatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005075/en/
Contacts
Ten Bridge Communications
Stephanie Simon, 617-581-9333
stephanie@tenbridgecommunications.com
